Swelling, Erosion, and Release Behavior of PEO/Primaquine Matrix Tablets

Abstract

Extended-release primaquine tablets were developed using polyethylene oxide (PEO) as a hydrophilic swellable polymer with different amounts and molecular weights (4´10 6 and 8´10 6 ). Investigations were carried out in order to verify the matrix performance. The evaluated parameters were weight, hardness, thickness, friability, and drug content. The swelling and erosion matrices as well as drug release profile were analyzed under dissolution conditions. The statistical model ANOVA and Tukey-Kramer HSD were considered. The results showed that all formulations provided adequate physical characteristics and a time release about eight hours following a non-Fickian diffusion model. The kinetics of drug delivery was directly related to the synchronization of swelling and erosion matrices. The formulations prepared with high PEO concentrations showed a lower rate of erosion, a slower drug release, and faster rate of swelling, as compared with matrices containing lower PEO concentration.

Polyethylene oxide matrix tablet swelling evolution: The impact of molecular mass and tablet composition

“…If the percolation threshold is not reached, the drug release from such PRTs can be uncontrolled and quite variable. Moreover, the outcome from dissolution results strengthens the research data that the gel layer robustness can be increased with a higher polymer proportion, resulting in a more uniform gel layer and a better-controlled drug release (3,43,48).…”

“…As a result, all three PEO tablets had disintegrated in at least 8 h, leading to a faster drug release (1,2,33,40,44). The same effect can also be gained with lower polymer concentrations in the matrix tablets (33,48).…”

Development and validation of a dissolution test for primaquine/polyethylene oxide matrix tablets

“…[8][9][10] Polyethylene oxide (PEO) was the hydrophilic polymer chosen due to its non-toxicity, nonionic nature and acceptable compatibility. 11 In vivo data has demonstrated that total PQ exposure in beagle dogs was 2.2 times higher (area under curve of 12 193 versus 5678 ng h/mL) with the matrix extended-release tablets compared with the immediate-release tablets.…”